Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Roles at http://pharmaceuticalintelligence.com

Research Category OWNER:

Population Health Management, Genetics & Pharmaceutical

 

Telephone: (781) 806-0275;

Email: alan.kaul@comcast.net

Alan F. Kaul, R.Ph., Pharm.D, M.Sc., M.B.A., FCCP 

PROFESSIONAL PROFILE

Highly accomplished health care professional in the pharmaceutical, biotechnical, and medical communications industries.

Experienced in strategic planning working with cross-functional teams such as Medical Affairs including health outcomes

departments, MSL team directors, business and marketing teams, and stakeholders. Ability to relate to clinicians, Key

Opinion Leaders (KOLs), and stakeholders in defining the economic and societal value of drugs and their place in therapy.

Core Competencies

• Pharmacoeconomic Analyses

• Accomplished Medical Author

• Extensive Knowledge of Pharma/Biotech Industries

• Scientific Presentation & Writing

• Team Leadership/Development

• Relationship Building with (KOLs) and Stakeholders

• Operations Management

• In-depth Hospital/Managed Care Experience Major Therapeutic Areas

• Neurological Disorders

• Diabetes

• Cardiovascular Disease

• Peripheral Vascular Disease

• Gastrointestinal Disease

• Pain Management

• Antimicrobials

• Osteoporosis

• Asthma

• Osteoarthritis

Practice Leader 1991-present

Medical Outcomes Management, Inc., Sharon, MA

• Founded a global health care management and technology consulting firm providing services including developing Population

Health Management (PHM) initiatives, pharmacoeconomic analyses, medical writing, KOL surveys, symposia, & publications

• Built a slide deck for a major biotechnology company to educate professional audiences on the role of comparative effectiveness research in medical decision-making. Sections included examples of pharmaco-economic methods including CBA, CUA, CEA, ICER, COI, and CMA; applied examples in several disease states

• Reviewed and recommended changes in Phase II/Phase III protocols for a biotechnology company considering clinical and economic outcomes of a direct-acting fibrinolytic agent

• Designed, conducted, presented findings, and published the results of multiple studies documenting the economic value of a thrombolytic agent in treating peripheral arterial occlusion and deep vein thrombosis

• Designed, completed, presented, and published findings comparing two macrolide antibiotics in treating COPD

• Designed, completed, presented, and published study findings by payer class comparing hypercholesterolemia management

• Designed, completed, presented, and published study findings comparing economic and clinical outcomes of a therapeutic interchange of proton pump inhibitors in a hospital setting

• Designed, completed, presented, and published analysis of floroquinolone use to treat acute cystitis in an ambulatory setting

• Developed tool to value customers’ attitudes towards role of Medical Scientific Liaisons (MSLs).

• Helped facilitate several mergers by coaching executives during integration of key brand teams & about 100 field-based MSLs

• Partnered with targeted KOLs creating innovative programs, identifying research and publication opportunities

• Created a toolset/organizational framework for the non-branded MSL team (MSL of a major pharmaceutical company.

• Documented economic value of client’s products and consulted in building a marketing campaign.

• Advised a Pharma company in designing & implementing a strategic plan using an economic model to expand their market.

• Produced a multi-platform PHM program for a culturally diverse and low literacy population.

• Collaborated to develop PHM program for a national HMO. Analyzed & presented financial and societal implications of findings

• Devised economic model for a medical device positioning it by identifying payback value to providers and insurers.

• Evaluated the accuracy of claims based analysis of congestive heart failure care for a large multi-state IPA model HMO.

• Served on Strategy Planning Group for Secondary Prevention of CHD of the AHA in developing Get With the Guidelines, a pivotal national initiative

• Developed provider education program for multi-site HMO; conducted focus groups, built algorithms, and trained staff in outreach skills.

• Created customizable PHM tools for a Pharma client to offer to its managed care customers.

• Conducted a benchmarking study for coronary heart disease prevention programs of the Texas Affiliate of AHA in collaboration with the Texas Medical Foundation & Texas Medical Association.

Director of Pharmacy Services August 2008-August 2011

Radius Specialty Hospital, Boston, MA

• Nationally recognized-by North American Thrombosis Forum in preventing DVT in patients 2010, 2011

• Reviewed/rewrote all TJC Medication Management (MM) Polices ensuring compliance with TJC & NPSG

• Instituted novel hospital-wide anticoagulant monitoring/prescribing service

• Integrated pharmacists into multi-disciplinary patient care team and shifted services to patient-centric model

Interim Director of Pharmacy September 2007-August 2008,

Health Alliance Hospitals – Leominister, (MA Multi-site Acute Care Hospital)

• Prepared Hospital & Department for TJC Survey by reviewing, revising, and validating hospital’s Medication Management EPs

and corrective action plans for 2007/8 and Departmental Policies and Procedures

• Reviewed departmental operational activities and recommended operational improvements

Project Manager 1990-1991

Lewin-VHI, Washington, DC

• Co-authored a managed care sales training manual for a multinational client.

• Created a strategic marketing plan for a pharmaceutical company in the managed care, long term care, federal, and hospital sectors.

• Helped client increase product line penetration and market share in price-sensitive marketplaces

• Consulted to a major teaching hospital developing a strategic reorganization plan.

Vice President for Clinical and Quality Assurance Services, Homecare Division 1988-1989

National Medical Care, Waltham, MA

• Planned training programs for clinicians, sales personnel, and general managers.

• Responsible for all clinical staff, clinical and QA programs, regulatory affairs, troubleshooting and inspections for 75 branches providing infusion therapy, respiratory therapy, and durable medical equipment.

• Developed multi-disciplinary clinical and QA meeting TJC standards.

• Identified and grew corporate synergy.

Director of Pharmacy Services 1974-1988

Brigham and Women’s Hospital, Boston, MA

• Responsible for a professional, technical, and clerical staff of 101 FTE’s, 9 cost centers, $$34 million in budgets. Managed specific financial, operational, clinical, research, and legal components of hospital.

• Consolidated and rebuilt three departments into a national leader in quality and innovative services.

• Instituted Investigational Drug and Drug Information services

Honors and Achievements: Awards

• Outstanding Alumni Award in Health Sciences, Northeastern University

• Delta Mu Delta National Honor Society in Business Administration.

• The Rho Chi Society Pharmaceutical Honor Society

• Fellow, American College of Clinical Pharmacy.

• Marquis Who’s Who in Science and Engineering 2001-3, 5th Edition

• Marquis Who’s Who in America 2003, 57th Edition; 2004, 58th Edition; 2006, 60th Edition

• Editorial Board Population Health Management (formerly Disease Management), 2004-date

Teaching Appointments

• Adjunct Professor of Pharmacy Practice, University of Rhode Island, 1997 – date

• Adjunct Clinical Professor of Pharmacy, Massachusetts College of Pharmacy and Allied Health Sciences,1982-88, 2002- date

• Lecturer in Obstetrics and Gynecology, Harvard Faculty of Medicine, 1986 – 1988

• Clinical Associate Professor of Pharmacy, Northeastern University, 1986 -1988

Publications and Presentations

• Authored more than 70 publications including original clinical research, case studies, and pharmacoeconomics in peer reviewed scientific journals

• Presenter in over 50 national, regional, and local lectures to professional and business organizations.

• Scientific reviewer for medical and pharmacy journals including Population Health Management , American Journal of Health-System Pharmacists, American Journal of Managed Care, Annals of Pharmacotherapy, , Journal of Managed Care Pharmacy,and Pharmacotherapy.

Organizations

• American College of Clinical Pharmacy

• Academy of Managed Care Pharmacy

• American Society of Health-System Pharmacists

• International Society for Pharmacoeconomics and Outcomes Research

• Society of Interventional Radiology

• American Academy of Pain Management

Education

• Pharm.D., University of Arkansas for Medical Sciences – December 2002

• M.B.A., Suffolk University, School of Management. – June 1980

• M.Sc., Pharmacology, Northeastern University – June 1976

• B.Sc. in Pharmacy, Northeastern University -June 1970

 

PUBLICATIONS, PRESENTATIONS, GRANTS AND RESEARCH

PUBLICATIONS

Kaul AF, Harsfield JC. Doxycycline and its indications; An updated review for the pharmacy and

therapeutics committee. Hosp Pharm 1975; 10:518-20.

Kaul AF, Harsfield JC. Propoxyphene hydrochloride or napsylate (letter)? Drug Intell Clin Pharm 1976;

10:53.

Kaul AF, Harsfield JC. Stability of aspirin in combination with propoxyphene hydrochloride and

propoxyphene napsylate (letter). N Engl J Med 1976; 294:907.

Horton TE, Kaul AF. Intravenous oxytocin infusion (letter). Drug Intell Clin Pharm 1977; 11:243.

Feldman MJ, Kaul AF. Oral hypoglycemic agents (letter). N Engl J Med 1977; 297:395.

Ericson AJ, Feldman MJ, Horton TE, Kaul AF. Neonatal medication surveillance (letter).

Am J Hosp Pharm 1977; 34:1302, 7.

Kaul AF, Harsfield JC, Osathanondh R, Ostheimer GW. Retrospective analysis of analgesics and

sedative-hypnotics in hospitalized obstetrical and gynecological patients. Drug Intell Clin Pharm 1978;

12:95-9.

Kaul AF. Pharmacotherapy and breast feeding. The Apothecary March/April 1978.

laminaria. J Reprod Med 1978; 20:213-8.

Harsfield JC, Kaul AF. Personnel requirements for improving services in hospital pharmacy. Hosp Pharm

1978; 13:264-7, 301.

Souney PF, Feldman MJ, Kaul AF. Dexamethasone for respiratory distress syndrome (letter).

Drug Intell Clin Pharm 1979; 13:526-7.

Souney PF, Churchill WW, Kaul AF. Mefenamic acid for dysmenorrhea (letter). JAMA 1979; 242:2393-4.

Feldman MJ, Souney PF, Kaul AF. Determining the date of manufacture of drug products from lot

numbers. Am J Hosp Pharm 1979; 36:1545-7.

Souney PF, Churchill WW, Kaul AF. Use and preparation of Schillers solution (letter). Am J Hosp Pharm

1980; 37:1048.

King W, Kaul AF. Determining phenytoin dosage with the use of a programmable calculator.Drug Intell

Clin Pharm 1980; 14:684-93.

Kaul AF, Stubblefield PG. Terbutaline sulfate overdosage. Drug Intell Clin Pharm 1980; 14:866.

Churchill WW, Souney PF, Kaul AF. Cancer chemotherapy (letter). Am Pharm 1980; 20:4.

Kaul AF, Jewett JF. Agents and techniques for disinfection of the skin: A review of the literature. Surg

Gynecol Obstet 1981; 152:677-85.

Kaul AF, Powell SH, Cyr DA. Postgraduate pharmacy fellowships. Drug Intell Clin Pharm 1981; 15:981-5.

Kaul AF, Jewett JF. Agents and techniques for disinfection of the skin: A review of the literature. J

Enterostomal Ther 1981; 8:19-25.

Kaul AF, Souney PF, Osathanondh R. A review of possible toxicity of di-2-ethylhexylphthalate (DEHP) in

plastic intravenous containers: Effects on reproduction. Drug Intell Clin Pharm 1982;6:689-92.

Kaul AF, Milochuk JA. Pediatric Therapy-Drugs and breastfeeding. On Continuing Practice 1982; 9:31-5.

Kaul AF, Vogenberg FR, Harsfield JC. Simplified method of calculating and recording the use of tax free

alcohol. Am J Hosp Pharm 1982; 39:1525-8.

Kaul AF, Powell SH, Wilson JA. Postgraduate pharmacy fellowships (1982-1983). Drug Intell Clin Pharm

1982; 16:949-53.

Souney PF, Kaul AF, Osathanondh R. Pharmacotherapy of premature labor.

Clin Pharm 1983; 2:29-44.

Benfell KE, Powell SH, Kaul AF. A Comprehensive pharmacy based investigational drug service. Am J

Hosp Pharm 1983; 40:64-7.

Osathanondh R, Kaul AF, Souney PF. Zomepirac sodium for primary dysmenorrhea syndrome (letter). N

Engl J Med 1983; 308:401.

Souney PF, Cyr DA, Chang JT, Kaul AF. Sugar content of selected pharmaceuticals.

Diabetes Care 1983; 17:293.

Kaul AF, Souney PF, Osathonondh R. Comment of DEHP toxicity (letter). Drug Intell Clin Pharm 1983;

17:293.

Feldman MJ, Churchill WW, Souney PJ, Fretthold RA, Kaul AF. Improved drug distribution in a clinical

research center. Am J Hosp Pharm 1983; 40:1020-2.

Churchill WW, Souney PF, Feldman MJ, Kaul AF. Decentralized preparation of short term prescriptions for discharged patients. Am J Hosp Pharm 1983; 40:2153-5.

Feldman MJ, Mantel SA, Kaul AF. A comparison of the practices used for distribution of controlled

substances in Massachusetts hospitals with those reported nationally. Hosp Pharm 1983; 18:597-9.

Kaul AF, Powell SH, Miller CR. Postgraduate pharmacy fellowships (1983-1984). Drug Intell Clin Pharm

1983; 17:912-3.

Vogenberg FR, Schwartz PA, Kaul AF, Powell SH, Benfell K. Expansion of an investigational drug service

(letter). Drug Intell Clin Pharm 1983; 17:835-9.

Kaul AF. Review of The Individual’s Guide to Grants by Margolin JB. Drug Intell Clin Pharm 1984; 18:88.

Kaul AF, Powell SH, Miller CR. Correction to postgraduate pharmacy fellowships (letter). Drug Intell Clin Pharm 1984; 18:325-6.

Owens OM, Kaul AF, Schiff IM, Burt RAP. Efficacy of fenoprofen in the prevention of pain associated with

hysterosalpingograms (abstract). Drug Intell Clin Pharm 1984; 18:496-7.

Owens OM, Schiff IM, Kaul AF, Cramer DC, Burt RAP. Reduction of pain following hysterosalpingogram

by prior analgesic administration. Fertility and Sterility. 1985; 43:146-8.

Osanthanondh R, Caldwell BV, Kaul AF, Sokoloff BJ, White RM, Scavone JM, Burt RAP, Naftolin F.

Efficacy of fenoprofen in the treatment of primary dysmenorrhea. J Reprod Med 1985; 30:915-919.

Churchill WW, Souney PF, Fretthold RA, Kaul AF. Medication carts, are they all the same? Hosp Pharm

1985; 20:837-43.

Rayment C, Kaul AF, Garfield J. Comparative acceptance of three transdermal nitroglycerin placebo

patches. Amer J Hosp Pharm 1985; 42:1362-5.

Powell SH, Fanikos JR, Kaul AF. Positions held by graduates of postgraduate pharmacy fellowship

programs. Drug Intell Clin Pharm 1985; 19:57-9.

Kaul AF, Osanthanondh R, Safon LE, Frigoletto FD Jr., Friedman PA. The management of preterm labor

with the calcium channel blocking agent nifedipine combined with the betamimetic terbutaline. Drug Intell Clin Pharm 1985; 19:369-71.

Kaul AF, Powell SH, Stachowski JS. Postgraduate pharmacy fellowships (1984-1985).

Drug Intell Clin Pharm 1985; 19:219-24.

Osathanondh R, Caldwell BV, Kaul AF, Sokoloff BJ, White RM, Scavone JM, Naftolin F, Burt RAP.

Efficacy of fenoprofen in the treatment of primary dysmenorrhea (abstract).

Drug Intell Clin Pharm 1985; 19:445.

Kaul AF. Prospective payment and diagnosis-related groups. Emerging Issues in Hospital Pharmacy

1985; 1:Number 3:1-6.

Powell SH, Oulette SM, Kaul AF. Increasing hospital pharmacy residents’ management training (letter).

Am J Hosp Pharm 1985; 42:532-3.

Souney PF, Churchill WW, Kaul AF. Cost of implementing and maintaining a hospital-pharmacy-based online

literature system. Am J Hosp Pharm 1985; 42:2496-8.

Kaul AF, Janosik JE, Powell SH. Postgraduate pharmacy fellowships (1985-1986).

Drug Intell Clin Pharm 1986; 20:203-8.

O’Neill S, Osanthanondh R, Kaul AF, Scavone JM, Bromley BS, Malin MA. The pharmacokinetics of

nifedipine in pregnant women (abstract). Drug Intell Clin Pharm 1986; 20:460.

Kaul AF, Epstein J, Powell SH. Postgraduate pharmacy fellowships (1986-1987).

Drug Intell Clin Pharm 1987; 21:205-10.

Figge H, Huang V, Kaul AF, Demling RH. The pharmacotherapy of the behavioral manifestations of the

ICU syndrome. J Crit Care 1987; 2:199-205.

Lief PA, Reisman R, Kaul AF, Rocco A, McKay W, Benfell K. Comparision of intravenous regional

guanethidine and reserpine to relieve the pain of reflex sympathetic dystrophy (abstract). Drug Intell Clin

Pharm 1987; 21:7A-8A.

Rocco AG, Frank ED, Kaul AF, Reisman RM, McKay WR, Ferrante FM. Comparison of epidural morphine,

epidural triamcinolone, and epidural morphine combined with triamcinolone in the treatment of recurrent

low-back pain (abstract). Drug Intell Clin Pharm 1987; 21:18A.

Harrington RE, Kaul AF. Cardiopulmonary arrest following barium enema examination with

glucagon. Drug Intell Clin Pharm 1987; 21:721-2.

Kaul AF. Correction: Postgraduate pharmacy fellowships (letter). Drug Intell Clin Pharm 1987; 21:549.

Lief PA, Reisman R, Rocco A, McKay W, Kaul AF, Benfell, K. I.V. regional guanethidine vs. reserpine for

pain relief in reflex sympathetic dystrophy (RSD); Controlled randomized double blind, crossover study

(abstract). Pain 1987; Supplement 4:S205.

Kaul AF, Johnson EG, Powell SH. Postgraduate pharmacy fellowships (1987-88).

Drug Intell Clin Pharm 1988; 22:168-72.

Figge HL, Figge J, Souney PF, Sacks FB, Shargel L, Janosik JE, Kaul AF. Comparison of excretion of

nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man. J Clin

Pharmacol 1988;28:1136-40.

Rocco AG, Frank E, Kaul AF, Lipson SJ, Gallo JP. Epidural steroids, epidural morphine and epidural

steroids combined with morphine in the treatment of post-laminectomy syndrome. Pain 1989; 36:297-303.

Rocco AG, Kaul AF, Reisman RM, Gallo JP, Lief PA. A comparison of regional intravenous guanethidine

and reserpine in reflex sympathetic dystrophy. A controlled randomized double-blind crossover study.

Clin J Pain 1989;5:205-9.

Janosik JE, Bettmann MA, Kaul AF, Souney PF. Therapeutic alternatives for subacute peripheral arterial

occlusion: Comparison by outcome, length of stay, and hospital charges. Invest Radiol 1991; 26:921-5.

Kaul AF. Designing and implementing a drug utilization review program. Drug Benefit Trends 1992;

4:Number 1:4, 6-9.

Kaul AF. Medical outcomes management and cost-benefit considerations: An overview. Invest Radiol

1994; 29 (Supplement 1):S59-S63.

Kaul AF. Review of Promotion of Pharmaceuticals: Issues, Trends, Opinions edited by Pathak DS,

Escovitz A, and Kucukarsian. J Pharm Tech 1994;10:75-6.

Kaul AF, Feldman MJ. R.Ph.s not ignored in privitization.(letter) Hospital Pharmacist Report 1994;8:13

Aforismo JF, Kaul AF. Acute cystitis in women: quinolone drug utilization evaluation (DUE) and potential

cost savings in an independent practice association (IPA) model health maintenance organization (HMO)

(abstract). Pharmocotherapy 1995;15:117.

Aforismo JF, Kaul AF, Tomondy PA, Parry GE, Staubach LB, Regalli G, Dine AP. Floroquinolone use for

acute cystitis in an IPA-model managed care organization. Am J Health Syst Pharm 1995;52:2702-4

Kaul AF. Pharmacoeconomic Considerations in Peripheral Arterial Thrombolytic Therapy. JVIR

1995;6:104S-110S

Braun L, Kaul AF. Health care delivery and economics: The impact of integrated delivery systems on drug

prescribing. Spectrum 1996;78:1-11.

Kaul AF, Tomera JF. DUE criteria for use of regional urokinase unfusion for deep vein thrombosis. Am J

Health System Pharm 1997;54:2002-3.

Kaul AF, Tomera JF. DUE criteria for use of regional urokinase unfusion for peripheral arterial occlusion.

Am J Health System Pharm 1997;54:2000-1

Tomera JF, Kaul AF Regional thrombolytic infusion for peripheral arterial occlusion and deep vein

thrombosis: Tried and true. Am J Health System Pharm 1997;54:1988-91.

Bramlet DA, King HM, Witt JR, Bosch RJ, Kaul AF. Cholesterol management by interventional and

invasive cardiologists: Results from a QA audit in patients with coronary heart disease. (Transcatheter

Cardiovascular Therapeutics Symposium Abstract 241) Am J Cardiol 1997: 80:67S

Bramlet DA, King HM, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia:

Practice patterns for primary care providers and cardiologists. Am J Cardiol 1997;80 (8B):39H-44H.

Bramlet DA, Stoukides CA, Kaul AF, Hsiao LD. A comparison of hypercholesterolemia in the secondary

prevention of coronary heart disease by payor types: Fee-for service, Medicare, and Managed Care

Organizations. J Managed Care Pharm 1998;4:483-7.

Kaul AF, Stoukides CA, Hsiao LD. Atorvastatin, another HMG CoA reductase inhibitor?

http:www.medscape.com/Medscape/cardiology/1999v03.n04/mc0713.01/pnt-mc0713.01.html

Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: Preliminary results of a

therapeutic interchange program. J Managed Care Pharm 1999;5:410-411 (abstract)

Stoukides CA, McVoy H, Kaul AF. Candesartan cilexetil review: An angiotensin II receptor blocker. Ann of

Pharmacotherapy 1999;33:1287-1298.

Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: Preliminary results of a

therapeutic interchange program. Am J Managed Care 2000;6: (accepted for publication)

Hillert B, Remonte S, Rodgers G, Yancy CW, Kaul AF. Improving patient outcomes by pooling resources

(The Texas Heart Care Partnership experience). Am. J. Cardiol 2000;85:43A-51A.

LaBresh KA, Owen P, Alteri C, Reilly S, Shea-Albright P, Hordes AR, Shaftel PA, Noonan CA, Stoukides

CA, Kaul AF. Secondary prevention in a cardiology group practice and hospital setting after a Heart-Care

initiative. Am. J. Cardiol 2000;85:23A-29A.

Castaldo RS, Mato A, Stoukides CA, Kaul AF. Effect of patient education and zanamivir on morbidity of

influenza in a private practice. Chest 2000;4:244S (abstract)

Jan SA, Leach TD, Kaul AF. The formulary management system and decision-making process at Horizon

Blue Cross Blue Shield of New Jersey: review of osteoporosis and emerging treatment options. (Abstract

300) Pharmacotherapy 2001;21:1301

Castaldo RS, Mato A, Kaul AF, Gorski H, Bosch RJ. A retrospective analysis of cyclooxygenase-II

inhibitor response patterns. J Pharm Technol 2002;18:305-9

Ouriel K, Leonard MC, Kaul AF. Clinical and economic outcomes in the treatment of peripheral occlusive

diseases. © 2003, Medical Outcomes Management, Inc.

Ouriel K, Kaul AF, Leonard MC, Katzen BT. Clinical and economic outcomes in the treatment of peripheral

occlusive diseases. Society of Interventional Radiology Annual Meeting. Salt Lake City .March 30, 2003

(abstract #510) JVIR. 2003; 13:S

Thorpe PE, Kaul AF, Bosch RJ. Thrombolytic therapy versus anticoagulation for treatment of deep vein

thrombosis: 10 year clinical observations. (abstract #27) JVIR. 2004;15:S153

Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral

arterial occlusive disease and deep venous thrombosis. J Vasc Surg 2004;40:971-7.

Castaldo RS, Cifaldi M, Kaul AF, Castaldo A, Chopko M, Peterson B, Mato A, Treatment of Acute

Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: A

Retrospective, Cohort Analysis of Clarithromycin extended release vs. Azithromycin (abstract) Chest

2003:124;172S.

Woo A, Hittell J, Beardsley C, Noh, C, Stoukides CA, Kaul AF. An Ongoing Six-Year Innovative

Osteoporosis Disease Management Program: Challenges and Success in an IPA Physician Group

Environment. Disease Management 2004;7:216-225.

Castaldo RS, Cifaldi M, Mato A, Kaul AF. Treatment of Acute Exacerbations of Chronic Bronchitis in

Patients with Chronic Obstructive Pulmonary Disease: A Retrospective, Cohort Analysis of Clarithromycin

extended release vs. Azithromycin (submitted for publication)

Campinha-Bacote DL, Kendle JB, Jones C, Callicoat D, Webert A, Stoukides CA, Kaul AF, Shames C.

Impact of a Migraine Management Program on Improving Health Outcomes. Disease Management

2005:8;382-391

Jan SA, Kaul AF. Osteoporosis Treatment Options. 2006: J Managed Care Medicine:9 (1);11-21.

Nair V, Salmon JW, Kaul AF. Iatrogenic Disease Management: Moderating Medications Errors and Risks

in a Pharmacy Benefit Management Environment. Disease Management 2007:10:337-346.)

BOOK CHAPTERS

Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 4th Edition. Shargel L, Mutnick AH,

Souney PF, Swanson LN (Editors).Baltimore MD. Lipincott Williams & Wilkins, 2000

Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 5th Edition.. Shargel L, Mutnick AH,

Souney PF, Swanson LN (Editors).Baltimore MD. Lipincott Williams & Wilkins, 2004

Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 6th Edition. Shargel L, Mutnick AH,

Souney PF, Swanson LN (Editors).Baltimore MD. Lipincott Williams & Wilkins, 2006

Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 7th Edition. Shargel L, Mutnick AH,

Souney PF, Swanson LN (Editors).Baltimore MD. Lipincott Williams & Wilkins, 2008

Kaul AF. Pain Management. In Comprehensive Pharmacy Review, 8th Edition. Shargel L, Mutnick AH,

Souney PF, Swanson LN (Editors).Baltimore MD. Lipincott Williams & Wilkins, (in press) 2012

PRESENTATIONS

The development of appropriate pharmacy services for the Boston Hospital for Women, with Harsfield J,

American Society of Hospital Pharmacists (ASHP), NYC, May 15-19, 1977.

Hospital pharmacist and generic drugs, broadcast on the Physician’s Radio Network,

April 18, 1979.

New applications for old drugs in obstetrics and gynecology, with Feldman M, Souney P, Wakamatsu L,

Massachusetts Society of Hospital Pharmacists (MSHP), Boston, May 5, 1979.

Pharmacy involvement in an outpatient oncology clinic, with Churchill WW, Souney P, Feldman MJ, MSHP

Spring Seminar, Boston, May 5, 1979.

A Comprehensive pharmacy based investigational drug service, with Benfell K, Powell SH, Midyear

Clinical Meeting (MCM), New Orleans, December 9, 1981

Decentralized distribution of discharge prescriptions, with Churchill WW, Souney PF, Feldman MJ,

Hassan TE, ASHP MCM, Los Angeles, December 7, 1982.

Factors affecting the selection and maintenance of unit dose carts, with Churchill WW, Souney

PF,Fretthold R, Beeler M, ASHP MCM, Atlanta, December 6, 1983.

The pathophysiology and treatment of angina pectoris, Long Island Society of Hospital Pharmacists,

Rockville Centre, NY, October 12, 1983.

Availability of low-volume vancomycin infused through a modified Y-site with peripheral nutrition solution

and fat emulsions, with Kosoglou T, Martin-Marx C, Eastern States Conference for Pharmacy Residents

and Preceptors (ESCPRP), Philadelphia, April 27, 1984.

Comparison of computer retrieval of drug information with Medline contrasted with Paperchase, with

Souney PF, Miller C, MSHP Spring Seminar, Framingham, MA, April 10, 1984.

Efficacy of fenoprofen in the prevention of pain associated with hysterosalpingograms, with Owens OM,

Schiff IM, Burt RAP, American College of Clinical Pharmacy (ACCP), San Diego, June 27, 1984.

Use of hospital based on-line computer searching, with Souney PF, Churchill WW, ASHP MCM, Dallas,

December 3, 1984.

Drug Information broadcast on radio station WRKO, Boston, August 14, 1984.

The application of quality circle concepts to promote teamwork among pharmacists in a highly centralized

pharmacy environment – A descriptive report, with Stempien MJ, Ouellette SM,

Powell SH, ASHP MCM, Dallas, December 3, 1984.

Retrospective analysis of perioperative antimicrobial use in TURP patients, with Colucci R, Luciw H,

Garnett R, Souney P, ESCPRP, Philadelphia, April 20, 1985.

Efficacy of fenoprofen in the treatment of primary dysmenorrhea, with Osathanondh R, Caldwell B,

Sokoloff B, White RM, Scavone JM, Naftolin F, Burt RAP, ACCP, Orlando, July 9, 1985.

A retrospective audit of amikacin usage in a large teaching hospital, with Souney PF, Luciw H, and Gasca

M, ASHP MCM, New Orleans, December 11, 1985.

A retrospective cost analysis of thrombolytic therapies compared to surgical thrombectomy in peripheral

arterial occlusions, with Janosik JE, Eastern States Conference for Pharmacy Residents and Preceptors,

Philadelphia, May 9, 1986.

The pharmacokinetics of nifedipine in pregnant women, with O’Neill S, Osathanondh R,Scavone JM,

Bromley BS, Malin M, ACCP, Chicago, July, 1986.

Transdermal drug delivery systems: Agents and their uses, Rochester Area Society of Hospital

Pharmacists, Rochester, NY, October 8, 1986.

Hormonal replacement therapy in post menopausal women, Hamilton County Pharmaceutical Association,

Cincinnati, October, 14, 1986.

New advances in hormonal replacement therapy, Northeast Society of Hospital Pharmacists, Albany, NY,

October 21, 1986.

Prophylactic antibiotic use, monitoring intensity and costs of infectious morbidity in women with Brown BL,

ASHP MCM, Las Vegas, December 9, 1986.

Pharmacology of estrogens, MSHP, Framingham, MA, December 17, 1986.

Career planning, keynote speaker, Northeastern University, Rho Chi Honor Society Induction Ceremony,

May 29, 1987.

Transdermal drug delivery systems, Northeastern University, Dedham, MA, May 31, 1987.

Comparison of epidural morphine, epidural triamcinolone, and epidural morphine combined with

triamcinolone in the treatment of low back pain, with Rocco A, Reisman R, McKay W, Ferrante FM,

ACCP, Austin, TX, July, 1987.

Comparison of intravenous regional guanethidine with reserpine to relieve the pain of reflex sympathetic

dystrophy, with Lief PA, Reisman R, Rocco A, McKay W, Benfell K, ACCP, Austin TX, July, 1987.

Approaches, perspectives, and overall implications of drug utilization review programs, Drug Utilization

Review: A Workshop, Yosemite National Park, May 4, 1991.

Pharmacoepidemiology in a teaching hospital, Hartford Hospital, Hartford, CT, August 6, 1987.

Pharmacy based investigational drug services, Michigan Society of Hospital Pharmacists Annual Meeting,

Detroit, MI, October 7, 1987.

Approaches, perspectives, and overall implications of drug utilization review programs, Drug Utilization

Review: A Workshop, Yosemite National Park, May 4, 1991.

Medical outcomes management and cost-benefit considerations, presented at Current

Considerations in Contrast Imaging – An International Forum in Aventura, FL , June 4-6, 1993.

The impact of drug therapy on outcomes management, OUTCOMES ‘93 Conference by Infoline in San

Diego, February 23-24, 1993 and Boston, March 23-24, 1993.

Acute cystitis in women: quinolone drug utilization evaluation (DUE) and potential cost savings in an

independent practice association (IPA) model health maintenance organization (HMO), with John

Aforismo. ACCP Winter Pracitce and Research Forum. Orlando February 14, 1995.

Pharmacoeconomic considerations in peripheral arterial thrombolytic therapy. Summit Meeting:

Thrombolytic Therapy in Peripheral Vascular Disease. Snowbird, UT. April 9, 1995.

Developing and implementing a disease state management program. (Rountable). Academy of Managed

Care Pharmacy (AMCP) 1995 Educational Conference. Washington DC. November 10, 1995.

Developing a disease management program for treating mild-to-moderate hypertension: A co-marketing

venture, with Aforismo JF, Hedblom EC. (Pharmacy Partnership Briefing) AMCP 1995 Educational

Conference. Washington DC Novermber 11, 1995.

Developing and implementing a disease state management (DSM) program, with Cheryl Stoukides.

Rhode Island Society of Hospital Pharmacists 1996 Continuing Education Program. Johnston RI Fbruary

27, 1996.

Cost outcomes in peripheral vascular disease. Lecture in Economic Outcomes in Intra-arterial

Thrombolysis Symposium at California Society of Health-System Pharmacists Focus ’96 Symposium.

Newport Beach CA March 29, 1996.

Value of economic outcomes. Lecture in Economic Outcomes in Intra-arterial thrombolysis. Symposium

at California Society of Health-System Pharmacists Focus ‘96

Symposium. Newport Beach CA March 29, 1996.

Thrombolysis versus surgery: clinical and economic considerations in treating peripheral arterial occlusive

disease. WV Society of Health System Pharmacists. Martinsburg WV May 3, 1996.

Comparing hypercholesterolemia management by payor types: with Bramlet DA and King HM, AMCP

1997 Educational Conference. Seattle, WA October 31, 1997.

Proton Pump inhibitor therapy: Preliminary results of a therapeutic interchange program. With Amidon PB,

Jankovich R, Stoukides CA. AMCP 1999 Educational Conference. Atlanta, GA October 8, 1999.

Developing Clinical Guidelines and Their Legal Implications. Washington Metropolitan Area Society of

Health-System Pharmacists Continuing Education Program. Bethesda, MD November 16, 2000.

Clinical and economic outcomes in the thrombolytic treatment of peripheral vascular occlusion. with

Ouriel K, and Katzen BT. Society of Interventional Radiology, March 30, 2003, Salt Lake City.

A Clinical Review of Thrombolytic Therapies: An Abloom Inc Faculty Forum. April 25-26, 2003. Chicago,IL.

Differentiating Thrombolytic Agents: Clinical Differentiation and Pharmacoeconioic Considerations.

Presented with SR Deitcher and MR Jaff as a series of 25 Telepoint Conferences web and voice

conferences for physicians and pharmacists April – June 2003

Differentiating Thrombolytic Agents: Considerations for Pharmacists. American Society of Health-System

Pharmacists Summer Meeting June 2, 2003 San Diego, CA

Clinical and economic outcomes in the thrombolytic treatment of peripheral vascular occlusion. with

Leonard MC, Ouriel K, and Katzen BT. American College of Clinical Pharmacy Meeting, Atlanta,

November 3, 2003.

Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Cohort

Analysis of Clarithromycin Extended Release vs. Azithromycin. with Castaldo RS, Cifaldi M, Mato P,

Castaldo A, Chopko M, Peterson B. Chest 2003 Annual International Scientific Assembly October 29,

2003. Orlando FL.

Ouriel K, Kaul AF, Leonard MC, Katzen BT. Clinical and economic outcomes in the treatment of peripheral

occlusive diseases. Society of Interventional Radiology Annual Meeting. Salt Lake City .March 30, 2003

(abstract #510)

Thrombolytic therapy versus anticoagulation for treatment of deep vein thrombosis:10-Year clinical

observation. With P Thorpe and RJ Bosch. Presentation #11, 2004 29th Annual Scientific Meeting, Society

of Interventional Radiology. Phoenix, AZ March 26, 2004.

Integrating disease management and economics: With V Nair. Round Table Session . AMCP Pharmacy

Educational Conference. Baltimore, MD October 14th, 2004.

Economic modeling as a disease management tool. With V Nair. Round Table Session AMCP Annual

Meeting Denver, CO April 21, 2005.

Integrating pharmacoeconomic modeling into your utilization management programs. Financial Research

Associates Advanced Industry Symposium on Drug Utilization and Formulary Design. – Immediate Cost

Control Strategies for Employers, Health Plans, and Pharmacy Benefit Managers. Washington DC

September 26, 2005.

Practical guide to disease management. With J. Warren Salmon and Vinit Nair , AMCP Educational

Conference. Nashville, TN October 6, 2005.

Disease management programs. Who benefits? Financial Research Associates Made in America 2006.

3rd Annual Taft-Hartley Benefits Summit. Las Vegas, NV February 14, 2006.

The role of disease management in improving pharmaceutical care. Medimpact 2006 Conference

Choices. La Jolla, CA March 3, 2006.

Disease management and drug evaluation. With J W Salmon and V Nair. AMCP Annual Meeting, Seattle,

WA April 6, 2006.

Pharmacy Managed Anticoagulation Therapy in a Hospital Setting: Preliminary Findings. With Lin JL,

Nardolillo DM, Patel A, and Abadi Y 44th ASHP Mid-Year Clinical Meeting, Poster Session. Las Vegas,

NV. December 7, 2009.

Using Microsoft Access 2003 to create a record keeping database to follow public health regulation. With

Nardolillo DM, Lin JL, Patel A, Goldman-Levine J. 44th ASHP Mid-year Clinical Meeting, Poster Session.

Las Vegas, NV. December 7, 2009.

GRANTS AND RESEARCH

Dista Research Grant 8081D,” A double blind parallel study to compare the analgesic efficacy and safety

of single, oral prophylactic doses of Nalfon 600 mg., aspirin650 mg., and placebo in ninety women

undergoing hysterosalpingograms.” IND #16,015.

“A comparative study of patient acceptance of marketed transdermal nitroglycerin products (Placebos).”

Funded by Ciba-Geigy, Key, and Searle.

“Analgesic activity of fenoprofen, aspirin, and placebo in the treatment of primary dysmenorrhea.” IND

#16,664. Funded by Eli Lilly and Co.

“Nifedipine versus terbutaline in the management of preterm labor.” IND #26,332.

“Clinical trials of meteneprost potassium vaginal suppository for cervical dilatation and softening in

preparation for first trimester abortions.” IND #20,864. Funded by the Upjohn Co.

“A comparison of regional IV guanethidine and reserpine analgesia for reflex sympathetic dystrophy.” IND #23,575”.

“A double-blind comparison of epidural steroids, epidural morphine, and epidural steroids combined with

morphine in the treatment of recurrent low-back syndrome